Thursday 2nd May 2024: PME have just made another all time high today - a intraday high of $112.59 before closing at $112.10.

PME, you've done it again!

And I still do not own any PME in my real money portfolios - just here on Strawman - where I paid between $20.16 and $27.87 per share back in the first half of 2020, and that position is showing a +50.92%p.a. return over the past 4 years despite me trimming the position all the way up. Just couldn't bring myself to pay up for them with real money, as they always look fully priced or expensive, however they just keep on rising regardless!

From Monday 18-March-2024, Pro Medicus (PME) will be in the S&P/ASX100 Index.

SP-DJI-Announces-March-2024-Quarterly-Rebalance.PDF

18-Aug-2021:  Excellent result from PME today, which resulted in their shares closing up +15.66% @ $65.35/share, another highest-ever-closing-price - they've been setting those on a reasonably regular basis during 2021.

To watch their CEO & MD, Dr. Sam Hupert, being interviewed about the result on Ausbiz this afternoon, use the following link:  https://www.ausbiz.com.au/media/pro-medicus-ceo-on-why-fy21-was-only-the-foundation-for-better-results?videoId=13707

He's pretty bullish on the future, and discusses the tailwinds that the company currently enjoys.

There was also an interview posted as an announcement to the ASX today - for further details on that, see here:  http://www.promed.com.au/dr-sam-hupert-interview-2/

Transcript of that interview here:  http://www.promed.com.au/wp-content/uploads/2021/08/CEO-Interview-FY-Results-2021.pdf

Results details can be viewed here:

http://www.promed.com.au/pro-medicus-limited-full-year-results-5/

Company announcement of results:  http://www.promed.com.au/wp-content/uploads/2021/08/Company-Announcement-Full-Year-Results-2020-21.pdf

HIGHLIGHTS

• Revenue $67.9m – up 19.5%
• Underlying profit before tax $42.6m – up 41.0%
• Net profit $30.9m – up 33.7%
• Cash and other financial assets $61.8m – up 42.4%
• Company remains debt-free
• Fully-franked final dividend 8c per share (total for the year 15c per share)
• Record number of new contracts announced during the period
• First FDA approved AI algorithm

Disclosure:  I hold PME in my SM virtual portfolio, but not in RL unfortunately.  Clearly I was wrong thinking they looked expensive in prior months and that I might get the chance to buy them cheaper.  This is one fluffy dog I am only going to be patting virtually it would seem, rather than in RL. 

Que sera, sera.

19-Feb-2021:  Sale of 1M shares each by founders

• Co-founders Dr Sam Hupert and Mr Anthony Hall have each sold 1 million PME shares during the current trading window
• The sale represents less than 4% of their respective shareholdings
• The sale to a number of local institutions was made at the closing price on 18 February 2021 without any discount.
• Dr Hupert and Mr Hall remain the two largest shareholders in the company with both founders retaining in excess of 27 million shares each.
• Their combined shareholdings after the sale represent in excess of 52% of the company’s shares on issue.

The Pro Medicus Board has been advised that co-founders Dr Sam Hupert and Mr Anthony Hall have sold 1 million shares each at the close of business on 18 February which is within the Company’s current trading window and represents less than 4% of their individual holdings.

Mr Peter Kempen Pro Medicus Chairman said “We announced in February 2018 that the Board had encouraged the founders to consider selling up to 3 million shares each, in order to improve the liquidity in the company’s shares. This latest transaction completes that process. The sale, to a number of local institutions, was done “at market” which reflects the very strong underlying demand for the company’s shares.”

Dr Hupert and Mr Hall re-affirmed that they do not intend to sell any further shares in PME in the foreseeable future. Mr Kempen added “Dr Hupert and Mr Hall remain actively engaged in the company and are committed to its future. This is evidenced by the fact that they remain the two key stake holders, with their combined holding post this recent sale being in excess of 52% of the shares on issue.”

--- ends ---

All good.  As you were.

15-Oct-2020:  PME signs A$10M deal with Ludwig-Maximilians University

PME signs A$10M – 7 year contract with Munich based Ludwig-Maximilians-Universität (LMU Klinikum)

HIGHLIGHTS

• PME signs 7-year, A$10M deal with LMU Klinikum
• LMU Klinikum is one of the largest university hospitals in Germany.
• Visage technology to be deployed throughout LMU Klinikum’s imaging departments replacing systems from legacy vendors
• Extends PME’s footprint in the European hospital segment

Leading health imaging company Pro Medicus Limited [ASX: PME] today announced its whollyowned German subsidiary, Visage Imaging GmbH, has signed a 7-year A$10million contract with Munich based Ludwig-Maximilians-Universität (LMU Klinikum) one of the largest university hospitals in Europe.

The contract will see the company’s Visage 7 technology implemented across all LMU Klinikum’s radiology and subspecialty imaging departments replacing existing legacy PACS systems with a single centralized instance of the Visage 7 Enterprise Imaging Platform. Visage is also used in the hospital’s state of the art operating theatre suite for HD video documentation and point-of-care Ultrasound archival and viewing.

LMU Faculty of Medicine is the largest medical training institution in southern Germany and regarded as one of the top academic hospitals in Europe.

The implementation is scheduled to commence in December 2020.

“We look forward to taking our partnership with Visage to the next level as we implement their technology across our radiology department,” said Dr Kurt Kruber, CIO of LMU Klinikum. “The Visage platform provides a highly scalable and reliable platform combined with sophisticated clinical features that will support us in both day-to-day patient care and advanced research.”

“We are very excited about this project,” said Dr Malte Westerhoff, Managing Director of Visage Imaging GmbH. “LMU Klinikum is a thought leader in making a digital strategy a core principle of their operations. We are confident that our technology and expertise can make a significant contribution to helping LMU Klinikum further enhance efficiency and achieve better patient outcomes.”

“Traditionally, large European teaching hospitals like LMU Klinikum have standardised on IT platforms from large, multinational imaging equipment (modality) vendors making this a difficult market to penetrate.” said Dr Hupert. “So this is a very significant milestone for us in this highly competitive market.”

--- ends ---

About Pro Medicus Limited:  Pro Medicus Limited [ASX: PME] is a leading medical imaging IT provider. Founded in 1983, the company provides a full range of radiology IT software and services to hospitals, imaging centres and health care groups worldwide. In late January 2009, the company announced the purchase of Visage Imaging, which has become a global provider of leading edge enterprise imaging solutions, pioneering the best-of-breed, or Deconstructed PACS® enterprise imaging strategy. Visage 7 technology delivers amazingly fast, multi-dimensional images streamed via an intelligent thin-client viewer. The company offers a leading suite of RIS, PACS and e-health solutions constituting one of the most comprehensive end-to-end offerings in radiology. Pro Medicus has global offices in Melbourne, Berlin and San Diego. www.promed.com.au

20-Aug-2020:  PME Full year results   and   FY2020 Results Presentation   plus   Preliminary Final Report   and   Full Year Statutory Accounts   and   Interview with CEO - Full year results

No matter how good the company is, and Pro Medicus is a VERY good company, there can still sometimes be a disconnect between the market's expectations, and reality, and in this case the market obviously had higher expectations than what PME delivered for FY20, and so PME have been sold down by around -2% to -3% today.  They're actually still closer to their $14.50 12-month low than they are to their $38.39 12-month high, but neither of those prices was reasonable.  One was rediculously expensive and the other was very cheap.  PME is another I'd like to buy into on a decent pullback.  We're not there let, but if they drift below $20/share I'll be giving them some serious consideration.